114. Ann Oncol. 2018 Apr 26. doi: 10.1093/annonc/mdx803. [Epub ahead of print]PIK3CA mutations are associated with reduced pathological complete response ratesin primary HER2-positive breast cancer: pooled analysis of 967 patients from fiveprospective trials investigating lapatinib and trastuzumab.Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, SchemC, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart M, von Minckwitz G,Baselga J.DOI: 10.1093/annonc/mdx803 PMID: 29701763 